Bispecific HER2 ligands for cancer therapy
AssigneeUniversitäT ZüRich
InventorsRastislav Tamaskovic, Martin Schwill, Andreas Pluckthun, Christian Jost
Life of this patent
Estimating the term…
Abstract
The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
Claims22
A bispecific HER2 targeting agent comprising an amino acid sequence as set forth in SEQ ID 03, SEQ ID 04, SEQ ID 05, SEQ ID 06, SEQ ID 07, SEQ ID 08, SEQ ID 09, SEQ ID 58, or SEQ ID 59.
A bispecific HER2 targeting agent comprising an amino acid sequence as set forth in SEQ ID 102, SEQ ID 103, SEQ ID 104, SEQ ID 105, SEQ ID 106, SEQ ID 107, SEQ ID 108, SEQ ID 109, or SEQ ID 110.
Dependencies are inferred from the claim text.